One of the most significant advancements in H&N oncology of the precedent decade is the demonstration that cancer patients with HPV-mediated HNSCC, particularly in the oropharynx, have p16 protein expression and are associated with significantly improved treatment outcomes expressed as higher rate of patients’ survival, compared to HPV-negative patients [6,33]. The gene discussed is CDKN2A; the disease is cancer.